Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josephine Chan

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Seizure|November 10, 2024
A global survey of telemedicine use in epilepsy care - practices before, during and after the COVID-19 pandemicHsiang-Yu Yu, Mamta Bhushan Singh, Josephine Chan, et al.
Seizure|February 21, 2023
Telemedicine for Individuals with epilepsy: Recommendations from the International League Against Epilepsy Telemedicine Task ForcePauline Samia, Jitendra Kumar Sahu, Amza Ali, et al.
Seizure|March 3, 2026
Applications and impact of telemedicine for persons with epilepsy: a scoping reviewJitendra Kumar Sahu, Ana Carolina Coan, Josephine Chan, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Seizure|November 10, 2024
A global survey of telemedicine use in epilepsy care - practices before, during and after the COVID-19 pandemicHsiang-Yu Yu, Mamta Bhushan Singh, Josephine Chan, et al.
Seizure|February 21, 2023
Telemedicine for Individuals with epilepsy: Recommendations from the International League Against Epilepsy Telemedicine Task ForcePauline Samia, Jitendra Kumar Sahu, Amza Ali, et al.
Seizure|March 3, 2026
Applications and impact of telemedicine for persons with epilepsy: a scoping reviewJitendra Kumar Sahu, Ana Carolina Coan, Josephine Chan, et al.
Pageof 2